News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Targeting EGFR Bests Standard Chemo in NSCLC, Tohoku University Study



6/24/2010 7:08:26 AM

MedPage Today -- In selected patients with metastatic non-small cell lung cancer, the targeted therapy gefitinib (Iressa) significantly prolongs the period before the disease progresses, researchers said.

Read at MedPageToday
Read at BusinessWeek


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES